AP 402
Alternative Names: AP-402Latest Information Update: 22 Nov 2024
Price :
$50 *
At a glance
- Originator AP Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 01 Nov 2024 AP Biosciences has patents pending for AP 402 in multiple countries (AP Biosciences website, November 2024)
- 01 Nov 2024 Preclinical trials in Solid tumours in Taiwan (IV)
- 01 Nov 2024 AP Biosciences plans to submit IND application for Solid tumours in Australia in Q4 2024 (AP Biosciences website, November 2024)